Newsroom
Some extra words about news and articles here to give search engines more food for thought
BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE…
Sepsis-finding biotech Prenosis lands $40M in financing, federal contract
Release originally posted on Crain’s Chicago Business Chicago-based sepsis diagnosing biotech Prenosis announced two $20 million milestones this morning, Series A financing and a large government contract. Read full release >
Prenosis Secures $40M to Advance Precision Medicine Infrastructure for Critical Care
Release originally posted on hlth.com Prenosis has announced the completion of a $20M Series A financing round alongside a $20M federal contract from the Biomedical Advanced Research and Development Authority (BARDA), bringing total new funding to $40M. The…
Chicago biotech startup Prenosis raises $40M to advance AI sepsis diagnostic tool
Release originally posted on Chicago Business Journal A local medtech startup behind an AI sepsis diagnostic tool recognized by TIME magazine has landed $40 million in funding. Read full release >
Prenosis Secures $40M to Build the Precision Medicine Network for Critical Care
Release originally posted on HIT Consultant The Chicago-based health tech company Prenosis revealed a dual milestone: the closing of a $20M Series A financing round and the awarding of a $20M contract from the Biomedical Advanced Research and Development Authority…
Prenosis Announces $20M BARDA Contract and $20M Series A Financing Round, Advancing Mission to Deliver Integrated Diagnostics and Therapeutics
Latest fundraising efforts accelerate further innovation in biology-based diagnostics and therapeutics for critical care conditions CHICAGO, IL – January 29, 2026 – Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics,…
Prenosis Named Winner of the 24th Annual Chicago Innovation Awards
Company’s AI-powered diagnostic is shaping the future of sepsis care CHICAGO, IL – November 14, 2025 – Prenosis has been named a winner of the 24th Annual Chicago Innovation Awards, the region’s foremost recognition of the most innovative new products and services…
Prenosis Named Finalist in 2025 Digital Health Hub Foundation Awards
Finalist recognition validates Prenosis’ pioneering work in AI-driven diagnostics for sepsis and its impact on critical care decision-making Chicago, IL – October 8, 2025 — Prenosis has been named a Finalist in the 2025 Digital Health Hub Foundation: Digital Health…
New ICD-10-PCS Code Available for AI Sepsis Diagnostic Tools
Prenosis’ Sepsis ImmunoScore™, Innovative Sepsis Diagnostic Technology, Now Supported by Enhanced Documentation and Reimbursement Pathway CHICAGO, IL – October 1, 2025 – The Centers for Medicare & Medicaid Services (CMS) has officially released the FY 2026…
Sepsis-finding biotech Prenosis lands $40M in financing, federal contract
Release originally posted on Crain’s Chicago Business Chicago-based sepsis diagnosing biotech Prenosis announced two $20 million milestones this morning, Series A financing and a large government contract. Read full release >
Prenosis Secures $40M to Advance Precision Medicine Infrastructure for Critical Care
Release originally posted on hlth.com Prenosis has announced the completion of a $20M Series A financing round alongside a $20M federal contract from the Biomedical Advanced Research and Development Authority (BARDA), bringing total new funding to $40M. The…
Chicago biotech startup Prenosis raises $40M to advance AI sepsis diagnostic tool
Release originally posted on Chicago Business Journal A local medtech startup behind an AI sepsis diagnostic tool recognized by TIME magazine has landed $40 million in funding. Read full release >
Prenosis Secures $40M to Build the Precision Medicine Network for Critical Care
Release originally posted on HIT Consultant The Chicago-based health tech company Prenosis revealed a dual milestone: the closing of a $20M Series A financing round and the awarding of a $20M contract from the Biomedical Advanced Research and Development Authority…
High-Profile Start-Ups Inato And Prenosis Show AI ‘Best Practice’
Article originally published in Forbes on May 22, 2025 Prenosis featured in article by author Michael L. Millenson, covering innovations at the 2025 MedCity INVEST conference in Chicago. “Treating artificial intelligence as just one ingredient in a business…
Sepsis ImmunoScore® Featured in JAMA
In a recent article titled “FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine,” published in JAMA by three senior FDA officials, Prenosis’ Sepsis ImmunoScore® was highlighted as a pivotal example of an AI…
Prenosis CEO Bobby Reddy, Jr. Recognized Among Crain’s Chicago 40 Under 40
Bobby Reddy, Jr., Co-Founder and CEO of Prenosis, has been named one of Crain’s Chicago Business 40 Under 40 for his visionary work in precision diagnostics and AI innovation. Under Bobby’s leadership, Prenosis has developed the Sepsis ImmunoScore™, the first…
Bobby Reddy, Jr. Discusses the Transformative Impact of AI on Sepsis Care–NewsNation Now
Bobby Reddy, Jr., Co-founder and CEO of Prenosis, appeared live on NewsNation Now for an in-depth, one-on-one interview about the transformative role of artificial intelligence in sepsis care. Airing just days after the FDA authorized the Sepsis ImmunoScore™, the…
Roche to distribute Prenosis’ AI sepsis detection tool in US–MedTech Dive
MedTech Dive, a trusted source for news and analysis in the medical technology industry, reports on Roche’s partnership with Prenosis. The Sepsis ImmunoScore™, a groundbreaking AI-powered tool, is available on Roche’s Navify Algorithm Suite, marking a…
BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease
Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE…
Prenosis Announces $20M BARDA Contract and $20M Series A Financing Round, Advancing Mission to Deliver Integrated Diagnostics and Therapeutics
Latest fundraising efforts accelerate further innovation in biology-based diagnostics and therapeutics for critical care conditions CHICAGO, IL – January 29, 2026 – Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics,…
Prenosis Named Winner of the 24th Annual Chicago Innovation Awards
Company’s AI-powered diagnostic is shaping the future of sepsis care CHICAGO, IL – November 14, 2025 – Prenosis has been named a winner of the 24th Annual Chicago Innovation Awards, the region’s foremost recognition of the most innovative new products and services…
Prenosis Named Finalist in 2025 Digital Health Hub Foundation Awards
Finalist recognition validates Prenosis’ pioneering work in AI-driven diagnostics for sepsis and its impact on critical care decision-making Chicago, IL – October 8, 2025 — Prenosis has been named a Finalist in the 2025 Digital Health Hub Foundation: Digital Health…
New ICD-10-PCS Code Available for AI Sepsis Diagnostic Tools
Prenosis’ Sepsis ImmunoScore™, Innovative Sepsis Diagnostic Technology, Now Supported by Enhanced Documentation and Reimbursement Pathway CHICAGO, IL – October 1, 2025 – The Centers for Medicare & Medicaid Services (CMS) has officially released the FY 2026…
Prenosis Named One of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards
Chicago-based Prenosis recognized for pushing the boundaries of biology and AI in acute care innovation CHICAGO, IL – September 24, 2025 – Prenosis has been named one of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards, which celebrates the most…
Prenosis Named Quarterfinalist in 2025 Digital Health Hub Foundation Awards
Recognition highlights Prenosis’ leadership in integrated diagnostics and therapeutics and its mission to bring clarity to critical care decisions CHICAGO, IL – September 15, 2025 – Prenosis has been selected as a quarterfinalist for the 2025 Digital Health Hub…
Sepsis ImmunoScore Named Honoree in Fast Company’s 2025 World Changing Ideas Awards
Annual Awards Recognize Innovative Companies and Projects Addressing the World’s Most Urgent Challenges CHICAGO, IL [June 10, 2025] — Prenosis is proud to announce that Sepsis ImmunoScore™ has been named an honoree of Fast Company ’s 202 5 World Changing Ideas…
Bobby Reddy, Jr. Named to TIME’s 2025 TIME100 Health List
Prenosis CEO and co-founder honored as one of the 100 most influential people in global health this year CHICAGO, IL – May 8, 2025 – Prenosis, Inc., a leader in precision diagnostics powered by artificial intelligence, today announced that its CEO and co-founder,…